A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors Meeting Abstract
| Authors: | Ott, P. A.; Callahan, M. K.; Odunsi, K.; Park, A. J.; Pan, L. S.; Venhaus, R. R.; Karakunnel, J. J.; Hodi, F. S.; Wolchok, J. D. |
| Abstract Title: | A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036904715 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2015.33.15_suppl.tps3099 |
| Notes: | Meeting Abstract: TPS3099 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work